Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Completes Acquisition of Affymetrix

NEW YORK (GenomeWeb) – Thermo Fisher Scientific announced today that it has completed its anticipated acquisition of Affymetrix for $14.00 per share in cash, for a total purchase price of approximately $1.3 billion, following approval of the merger agreement by Affy stockholders at a special meeting.

The merger, which was initially announced in January, went forward despite two weeks of upheaval, beginning with a competing bid by a new company formed by formed Affy executives — Origin Technologies — on March 18. After its first bid was rejected, Origin followed with a second, higher offer, which Affy also rejected this week. Origin then withdrew.

Following this, the law firm of Faruqi & Faruqi announced yesterday that it had filed a class action lawsuit in the United States District Court for the Northern District of California on behalf of Affy's shareholders in connection with the proposed sale to Thermo Fisher.

But despite the disruptions, the shareholders voted in a planned meeting today to go forward with the acquisition.

"We are pleased to announce the completion of this transaction and officially welcome the Affymetrix team," Thermo Fisher President and CEO Marc Casper said in a statement. He further added that the acquisition is a positive development for both companies, and it has given Thermo Fisher an expanded antibody portfolio that strengthens its leadership in the biosciences space, as well as "new genetic analysis capabilities to better serve clinical and applied markets."

"Our combined capabilities will benefit our customers, employees and shareholders, and we are excited to move forward as one organization positioned for growth," he said.

As a result of the completion of the transaction, Affymetrix stock will cease trading and will no longer be listed on the Nasdaq.

Shares of Thermo Fisher were up about half a percent at $141.50 in Thursday afternoon trading on the New York Stock Exchange.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.